Nicholas K Foreman
Overview
Explore the profile of Nicholas K Foreman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
156
Citations
4977
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu J, Edwards Mayhew R, Imbornoni L, Jung J, Oliver S, Foreman N, et al.
J AAPOS
. 2025 Mar;
:104178.
PMID: 40086744
Background: An adverse effect of mitogen-activated protein kinase (MEK) inhibitors is MEK inhibitor-associated retinopathy (MEKAR), a fluid collection between the retinal pigment epithelium (RPE) and interdigitation zone (IZ) seen in...
2.
Alimova I, Wang D, DeSisto J, Danis E, Lakshmanachetty S, Prince E, et al.
Mol Cancer Res
. 2025 Feb;
PMID: 39960392
Atypical teratoid rhabdoid tumor (ATRT) is a highly aggressive pediatric brain tumor driven by the loss of SMARCB1, which results in epigenetic dysregulation of the genome. SMARCB1 loss affects lineage...
3.
de Sousa G, Calzadilla A, Grimaldo E, Donson A, Sobral L, Jones K, et al.
Neuro Oncol
. 2025 Feb;
PMID: 39901723
Background: Posterior fossa molecular subtype A (PFA) ependymoma occurs in young children and is the deadliest subtype of pediatric ependymoma. High-risk subtypes with chromosome 1q+ and/or 6q- exhibit significantly poorer...
4.
Moertel C, Hirbe A, Shuhaiber H, Bielamowicz K, Sidhu A, Viskochil D, et al.
J Clin Oncol
. 2024 Nov;
43(6):716-729.
PMID: 39514826
Purpose: Pharmacologic therapies for neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PNs) are limited; currently, none are US Food and Drug Administration-approved for adults. Methods: ReNeu is an open-label, multicenter, pivotal, phase...
5.
Lim-Fat M, Bennett J, Ostrom Q, Touat M, Franceschi E, Schulte J, et al.
Neuro Oncol
. 2024 Oct;
27(1):13-32.
PMID: 39441704
Adolescents and young adults (AYAs; ages 15-39 years) are a vulnerable population facing challenges in oncological care, including access to specialized care, transition of care, unique tumor biology, and poor...
6.
Raybin J, Donson A, Foreman N, Vibhakar R, Handler M, Liu A
J Adv Pract Oncol
. 2024 Jul;
15(1):28-35.
PMID: 39055368
Purpose: Oncology advanced practitioners (APs) are on the front line in treating adverse effects. Among children with brain tumors, treatments such as craniospinal irradiation (CSI) cause neurocognitive injury, endocrinopathies, and...
7.
Walker F, Sobral L, Danis E, Sanford B, Donthula S, Balakrishnan I, et al.
Nat Commun
. 2024 May;
15(1):4616.
PMID: 38816355
Dynamic regulation of gene expression is fundamental for cellular adaptation to exogenous stressors. P-TEFb-mediated pause-release of RNA polymerase II (Pol II) is a conserved regulatory mechanism for synchronous transcriptional induction...
8.
OHalloran K, Hakimjavadi H, Bootwalla M, Ostrow D, Kerawala R, Cotter J, et al.
Mol Cancer Res
. 2024 May;
22(8):721-729.
PMID: 38691518
Little is known about the genomic alterations in chordoma, with the exception of loss of SMARCB1, a core member of the SWI/SNF complex, in poorly differentiated chordomas. A TBXT duplication...
9.
Zahedi S, Riemondy K, Griesinger A, Donson A, Fu R, Crespo M, et al.
bioRxiv
. 2024 Apr;
PMID: 38645202
Key Points: There is a developmental hierarchy in neoplastic population comprising of both progenitor-like and mature cell types in both PA and GG.A more immunogenic, immune activating myeloid population is...
10.
Griesinger A, Calzadilla A, Grimaldo E, Donson A, Amani V, Pierce A, et al.
Clin Cancer Res
. 2024 Feb;
30(8):1544-1554.
PMID: 38334950
Purpose: There are no effective treatment strategies for children with highest-risk posterior fossa group A ependymoma (PFA). Chromosome 1q gains (1q+) are present in approximately 25% of newly diagnosed PFA...